If approved by the EC, Wainzua would be the only approved medicine for the treatment of ATTRv-PN in the EU able to be self-administered with an autoinjector on a monthly basis. “Due to the progressive ...
(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...
Having additional amyloidosis treatment options designed to reduce the production of TTR protein at its ... Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, said: ...